vendredi 16 juin 2017

Onco Actu du 16 juin 2017

1. Biologie

Understanding Premalignancy and Cancer Risk [Cancer research Catalyst]

TCGA study of liver cancer reveals potential targets for therapy [NCI]

Swedish Study Rules 20 Years of Cancer Research Futile [Labiotech]

3.1 Tabac

Statement from FDA Commissioner Scott Gottlieb, M.D., on the 2016 National Youth Tobacco Survey results [FDA]

Teens' Use Of E-Cigarettes Drops For The First Time, CDC Says [NPR]

U.S. youth tobacco use in 2016 fell by largest amount in 6 years [Reuters]

Tobacco Use Among Middle and High School Students — United States, 2011–2016 [MMWR-CDC]

3.1.1 Tabac - e-cigs

No longer the hot new thing? Teen vaping falls, study says [STAT]

Electronic Cigarettes as an Introductory Tobacco Product Among Eighth and 11th Grade Tobacco Users — Oregon, 2015 [MMWR-CDC]

One third of U.S. adults don’t know e-cigarette vapor may harm kids [Reuters]

3.3 Prévention - Vaccins

Americans should be more afraid of HPV [Vox]

4. Dépistage, diagnostic et pronostic

Snapshots of Life: A Van Gogh Moment for Pancreatic Cancer [NIH Director's Blog]

5.10 Traitements - Essais

Advocating for a Return to Common Sense in Clinical Research [ASH Clinical News]

5.12 Immunothérapies

Tumor PD-L2 Expression May Predict Patient Response to Anti-PD-1 Immunotherapy [AACR]

5.12.3 Immunothérapies-combinaisons

Seattle Genetics and Bristol-Myers Squibb Highlight Interim Phase 1/2 Data Evaluating Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Relapsed Hodgkin Lymphoma at the International Conference on Malignant Lymphoma [BMS]

5.2 Pharma

Epizyme Reports Positive Interim Data from Phase 2 Trial for Tazemetostat in Relapsed or Refractory Follicular Lymphoma and DLBCL Patients [Epizyme]

Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J [The Street]

5.2.3 Pharma - économie

Checkmate Pharma Clinches $27M for More Studies in Skin Cancer [Xconomy]

Pharma companies fight behind-the-scenes wars over generic drugs [STAT]

Art Krieg comes down from the mountain with a $27M round for Checkmate Pharmaceuticals [EndPoints]

5.4 Traitements - Economie

Cost of Cancer Drugs Expected to Rise by Between 6 and 9 Percent [ASH Clinical News]

Final NICE nod for Takeda’s Adcetris in Hodgkin’s lymphoma [PharmaTimes]

Kadcyla new deal for breast cancer patients given green light in final draft guidance [NICE]

'Monumental U-turn' on cancer drug [BBC News]

Breast cancer drug that can extend lives approved for NHS use [The Guardian]

UK will pay for Roche breast cancer drug at center of price row [Reuters]

6. Lutte contre les cancers

Cancer's Big Infrastructure Problem [Forbes]

6.1 Observation

Are Rare Cancers on the Rise? [HealthLine]

6.3 Associations/Fondations

LifeArc, née MRC Technology, sets up high-risk seed fund [Xconomy]

Rebranded UK charity to stream £500m into medical research [PharmaTimes]

Keytruda bonanza inspires a facelift and plans to invest more than $600M in translational research [EndPoints]

6.4 Médico-éco

NICE to work with partners on developing new ways to measure quality of life across health and social care [NICE]

6.6 Publications

Meet PubPeer 2.0: New version of post-publication peer review site launches today [Retraction Watch]

6.7.2 Applis

Fostering Medical Innovation: A Plan for Digital Health Devices [FDA Voice]